Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation

A Decade of SG&A Evolution in Biotech

Comparing Operational Costs of Intra-Cellular Therapies and Bio-Techne

In the ever-evolving biotech landscape, understanding operational costs is crucial. Over the past decade, Bio-Techne Corporation and Intra-Cellular Therapies, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Bio-Techne's SG&A expenses have surged by over 550% from 2014 to 2023, reflecting its aggressive expansion and strategic investments. In contrast, Intra-Cellular Therapies, Inc. experienced a staggering 3,860% increase in the same period, highlighting its rapid growth trajectory. Notably, in 2023, Intra-Cellular Therapies surpassed Bio-Techne in SG&A expenses, marking a pivotal shift. This data underscores the dynamic nature of the biotech sector, where strategic financial management can significantly impact a company's competitive edge. As we look to the future, these trends offer valuable insights into the operational strategies of leading biotech firms.